Meet ChromaGenix.

We're advancing purification for complex biologics.

At ChromaGenix™, we help biopharma innovators overcome some of the most persistent challenges in drug development: how to purify complex biologics such as AAVs, mRNA, and viral vectors, more efficiently, consistently, and at scale.

Purpose-designed for advanced therapies.

We specialize in developing synthetic affinity ligands and chromatography resins that are engineered for the production of advanced therapies. Whether you’re working on gene therapy, vaccines, or emerging modalities, ChromaGenix is committed to solving your critical downstream challenges, backed by a culture of innovation, integrity, and scientific rigor.

Purification technologies for the next era of biomanufacturing.

ChromaGenix combines proven purification chemistry with investment, a new GMP facility, and a growing portfolio of high-performance tools. We also maintain a deep research partnership with NC State University for the ongoing development of novel, peptide-based affinity ligands to meet the evolving demands of modern bioprocessing.

Team

Chris Major

CEO

Michael Crapazano

Founder

Dr. Patrick Gilbert

Chief Operating Officer

Prof. Stefano Menegatti

Chief Scientific Officer

Michael Kaleja

EU Business Development Consultant

Ryan Hutchinson

Vice President – Commercial Development

Steve Tingley

Commercial Strategy Business Consultant

Sam Beales

Marketing Strategy Consultant

Scientific Advisory Board

Prof. Daniel Bracewell

Prof. Stefano Menegatti

Connecting you with process expertise, new purification technologies, new insights and collabration opportunities to shape and implement GMP-ready solutions.

view
join navigate

Evaluating AAV capture? Discover AvXcelTM

Our serotype-agnostic, alkaline-stable AAV affinity resin with flexible elution properties for higher recovery and preserved viral activity.

view

Form Title or Action Step

Put the form here instead of this text box.

Linkedin-in

Chris Major

CEO

Chris is responsible for identifying investment opportunities, assessing strategic fit within the portfolio, and supporting growth-related operational initiatives. A serial entrepreneur with over 20 years of bioprocessing experience, he has deep expertise across upstream and downstream technologies. Prior to BioProcess360, he founded and led the Purolite Bioprocessing division, growing it from zero revenue in 2015 to $80M in six years. The business was acquired by Ecolab (NYSE: ECL) in 2021 for $3.7BN. Earlier, Chris helped pioneer single-use technology at WAVE Bioreactors, later acquired by GE Healthcare (now Cytiva), and held senior roles at GE and Merck Millipore. He holds an MSc in Biotechnology and attended Harvard Business School. Outside work, Chris enjoys biking, paddleboarding, live music, and spending time with his two daughters.